Knee Osteoarthritis
Conditions
Keywords
glucosamine sulfate, individual differences, gene polymorphism
Brief summary
Glucosamine is an important part of the treatment strategy for osteoarthritis, but its effectiveness is still controversial. To explain the efficacy differences of glucosamine, in this study the investigators detect the concentration of glucosamine in the plasma and synovial fluid, some effect indexes such as inflammatory markers and gene polymorphism of glucosamine transporters. On the one hand, the investigators compare the plasma peak and gluten glucosamine concentration and the concentration in synovial fluid among participants to observe the individual differences of glucosamine exposure in vivo. On the other hand, the investigators investigate the correlation between drug concentrations, effect index and gene polymorphism. The hypothesis is that glucosamine exposure in vivo has individual differences and gene polymorphism can explain this differences.
Interventions
Patients taking glucosamine sulfate 1500mg every day for at least four days.
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. patients undergoing total knee arthroplasty for knee osteoarthritis; 2. 60-80 years.
Exclusion criteria
1. patients with severe liver or renal insufficiency; 2. patients allergic to glucosamine or any excipients in tablets; 3. patients who have been treated with glucosamine within three months; 4. patients who are unable to cooperate with the study; 5. continuous medication is less than 4 days; 6. patients with diarrhea, vomiting and other adverse reactions during medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Drug concentration in plasma | Fasting venous blood before the first administration | Drug concentration is measured by HPLC-MS/MS |
| Drug concentration in synovial fluid | During the operation of total knee arthroplasty | Drug concentration is measured by HPLC-MS/MS |
| Inflammatory markers in plasma | Fasting venous blood before the first administration | Leptin |
| Inflammatory markers in synovial fluid | During the operation of total knee arthroplasty | Leptin |
| Gene polymorphism | Fasting venous blood before the first administration | Gene polymorphisms of glucosamine transporters in vivo |
Contacts
Primary ContactQing Jiang
Backup ContactRuijuan Xu
Outcome results
None listed